Indaptus Therapeutics enters amended ATM equity distribution agreement for up to $100 million common stock offering

Shares may be sold from time to time through Wainwright as sales agent at prevailing market prices, subject to company-set daily size limits.

Sales under the new program start fresh versus the prior 2022 ATM; earlier sales do not count toward the $100 million cap.

The offering is tied to the company’s Form S-3 shelf registration statement, with a new prospectus supplement dated Aug. 31, 2026.

The company can suspend sales at any time; Wainwright has no obligation to buy shares as principal absent a separate terms agreement.

Indaptus Therapeutics entered an amended, restated at-the-market sales agreement with H.C. Wainwright for up to $100 million of common stock.